Low-Dose Ganaxolone for Absence Epilepsy

Solution Overview

Problem

Current treatments for absence epilepsy, including high doses of ganaxolone, often exacerbate symptoms due to overstimulation of GABAA receptors, and existing consensus suggests that ganaxolone is unsuitable for this condition, while it has shown promise for other forms of epilepsy.

Innovation Solution

Administering low doses of ganaxolone to restore optimal tonic inhibition, which is either deficient or excessively increased in absence epilepsy, thereby reducing seizure frequency and improving sleep disruptions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of ganaxolone are administered to treat absence epilepsy, then seizure control may be improved, but symptoms are exacerbated due to overstimulation of GABAA receptors

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameter from high doses to low doses of ganaxolone. Specifically, it identifies that low doses (0.2 to 2 mg/kg per dose) restore optimal tonic inhibition, while high doses cause overstimulation and symptom exacerbation. This parameter change resolves the contradiction by finding the optimal dose level that provides therapeutic benefit without harmful effects.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If ganaxolone is administered to treat absence epilepsy, then tonic inhibition can be restored, but existing consensus suggests ganaxolone is unsuitable for this condition

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the dosage parameter to low doses, which fundamentally alters the drug's suitability profile. At low doses, ganaxolone restores optimal tonic inhibition and is suitable for absence epilepsy, whereas at high doses it causes overstimulation and is considered unsuitable. This resolves the adaptability issue by identifying the specific dosage condition under which the drug becomes appropriate for this indication.

Inventive Principle:
Principle #35Parameter changes

3Object-affected harmful factors

If low doses of ganaxolone are administered, then adverse effects are avoided, but seizure frequency must be reduced effectively

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSProductivity

Solution Approach 1:

The patent identifies that low doses (0.2 to 2 mg/kg per dose) of ganaxolone achieve optimal tonic inhibition restoration without causing the overstimulation and adverse effects associated with high doses. Clinical data in the patent demonstrates that this low dose range effectively reduces absence seizure frequency while maintaining safety, thus resolving the contradiction between avoiding adverse effects and achieving therapeutic efficacy.

Inventive Principle:
Principle #35Parameter changes

4Reliability

If ganaxolone is used to treat absence epilepsy, then sleep disruptions can be addressed, but high doses cause thalamocortical dysfunction

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent identifies that low doses of ganaxolone normalize thalamocortical function and effectively treat associated sleep disorders, while high doses cause thalamocortical dysfunction and worsen sleep disruptions. By changing the dosage parameter to the low dose range, the patent resolves this contradiction and enables ganaxolone to be used safely for treating both absence epilepsy and sleep disruptions.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Low-dose ganaxolone effectively treats absence epilepsy by rescuing tonic inhibition, reducing absence seizures, and addressing associated sleep disorders by normalizing thalamocortical function without the adverse effects of higher doses.

Implementation Method 1

Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one, (3α, 5α)-3-hydroxy-3-methylpregnan-20-one, or CCD 1042) is a synthetic neurosteroid analogue that acts as a modulator of GABAA receptors

Methodology Applied
Scientific EffectGABAA receptor modulation:

Data Source

PatentUS10111889B2Uses of ganaxolone
Publication Date: 2018.10.30
  • US10111889B2 patent drawing
  • US10111889B2 patent drawing
  • US10111889B2 patent drawing

AI summary

Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.